1. Home
  2. ENTA vs HIT Comparison

ENTA vs HIT Comparison

Compare ENTA & HIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • HIT
  • Stock Information
  • Founded
  • ENTA 1995
  • HIT 1964
  • Country
  • ENTA United States
  • HIT United States
  • Employees
  • ENTA N/A
  • HIT N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • HIT Specialty Insurers
  • Sector
  • ENTA Health Care
  • HIT Finance
  • Exchange
  • ENTA Nasdaq
  • HIT Nasdaq
  • Market Cap
  • ENTA 164.6M
  • HIT 150.6M
  • IPO Year
  • ENTA 2013
  • HIT 2024
  • Fundamental
  • Price
  • ENTA $11.81
  • HIT $3.23
  • Analyst Decision
  • ENTA Strong Buy
  • HIT Strong Buy
  • Analyst Count
  • ENTA 5
  • HIT 1
  • Target Price
  • ENTA $20.20
  • HIT $2.50
  • AVG Volume (30 Days)
  • ENTA 1.1M
  • HIT 374.6K
  • Earning Date
  • ENTA 08-11-2025
  • HIT 11-16-2025
  • Dividend Yield
  • ENTA N/A
  • HIT N/A
  • EPS Growth
  • ENTA N/A
  • HIT N/A
  • EPS
  • ENTA N/A
  • HIT 0.02
  • Revenue
  • ENTA $64,806,000.00
  • HIT $26,692,318.00
  • Revenue This Year
  • ENTA N/A
  • HIT $70.02
  • Revenue Next Year
  • ENTA $1.65
  • HIT $63.39
  • P/E Ratio
  • ENTA N/A
  • HIT $172.39
  • Revenue Growth
  • ENTA N/A
  • HIT 29.68
  • 52 Week Low
  • ENTA $4.09
  • HIT $0.51
  • 52 Week High
  • ENTA $15.28
  • HIT $7.59
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 61.09
  • HIT 54.79
  • Support Level
  • ENTA $7.05
  • HIT $3.15
  • Resistance Level
  • ENTA $15.34
  • HIT $3.63
  • Average True Range (ATR)
  • ENTA 1.32
  • HIT 0.31
  • MACD
  • ENTA 0.47
  • HIT 0.00
  • Stochastic Oscillator
  • ENTA 53.86
  • HIT 57.63

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

Share on Social Networks: